Compare Incyte Corporation (INCY) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Raymond James Financial, Inc. — how do they compare? Incyte Corporation trades at $112.79 (market cap $22.85B), while Raymond James Financial, Inc. trades at $158.28 (market cap $30.51B). The key difference: Raymond James Financial, Inc. is the larger of the two by market cap, and Raymond James Financial, Inc. pays a 1.36% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and Raymond James Financial, Inc. for 75 Days on average.
| INCY | RJF | |
|---|---|---|
Market Cap | $22.85B | $30.51B |
Volume | 1,927,029 | 1,206,253 |
Sector | Health | Financials |
52-Week High | $129.93 | $181.18 |
52-Week Low | $83.80 | $140.89 |
Typical Hold Time | 33 Days | 75 Days |
Enterprise Value | $18.35B | $24.37B |
Dividend Yield | — | 1.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $112.75, down 0.61% on the day, with a bearish technical signal despite strong fundamentals. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline progress support growth prospects beyond JAKAFI's 2029 exclusivity loss. Analyst consensus is bullish with a $132.43 price target, though technical indicators show selling pressure near key resistance.
Outlook remains positive driven by pipeline diversification and operational leverage, but near-term technical weakness and reliance on JAKAFI transition pose risks. The stock offers value with a 14.36 P/E ratio and strong profitability metrics, though investors should monitor execution on the $4B non-JAKAFI sales target and quarterly earnings consistency.
Raymond James Financial (RJF) trades at $158.60, up 0.83% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 15.37% net margins and 18.48% ROE. Recent Q3 2026 results showed record revenues of $3.93 billion, beating expectations. The company continues dividend payments with a $0.54 quarterly payout declared for October 2026.
RJF presents a mixed outlook with strong fundamental performance offset by technical weakness. The 16% upside to consensus price target of $184.00 offers potential, but investors face headwinds from rising expenses and market volatility. The absence of sell ratings and consistent institutional interest supports the investment case, though technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
